Sickle Cell and Hemoglobin

  • Meet the Team

    The Sickle Cell and Hemoglobin program is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.

  • Show All

    Program Director

    A photo of Punam Malik, MD.

    Punam Malik, MD
    Marjory J. Johnson Chair of Gene and Cell Therapy

    513-636-1333

    punam.malik@cchmc.org

    Punam Malik, MD

    Marjory J. Johnson Chair of Gene and Cell Therapy

    Director, Comprehensive Sickle Cell Program

    Director, Translational Trials Development and Support Laboratory

    Program Leader, Hematology and Gene Therapy Program

    Professor, UC Department of Pediatrics

    Phone: 513-636-1333

    Fax: 513-636-1330

    Email: punam.malik@cchmc.org

    Show All

    Education and Training

    MBBS: University of Delhi, New Delhi, India, 1985.

    MD: University of Delhi, New Delhi, India, 1989.

    MS: University of Maryland, Baltimore, MD, 1991.

    Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

    Publications

    View PubMed Publications

    Clinical Director

    A photo of Karen Kalinyak.

    Karen A. Kalinyak, MD
    Medical Director, Sickle Cell Clinic

    513-636-4266

    karen.kalinyak@cchmc.org

    Karen A. Kalinyak, MD

    Medical Director, Sickle Cell Clinic

    Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-5845

    Email: karen.kalinyak@cchmc.org

    Show All

    Specialties

    Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy

    Education and Training

    MD: Temple University, Philadelphia, PA, 1977. 

    Residency: Children's Hospital Medical Center, Cincinnati, OH, 1980.

    Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1983.

    Certification: Pediatrics, 1984; Pediatric Hematology/Oncology, 1987.

    Publications

    View PubMed Publications

    Physicians

    Theodosia A. Kalfa, MD, PhD

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-0989

    Fax: 513-636-3549

    Email: theodosia.kalfa@cchmc.org

    Show All

    Specialties

    Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species

    Visit the Kalfa Lab.

    Education and Training

    MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.

    PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.

    Residency: University Of North Carolina, Chapel Hill, NC, 1999.

    Fellowship: Duke University Medical Center, Durham, NC, 2003.

    Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.

    Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.

    Publications

    View PubMed Publications

    Grants

    Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.

    Erythrocyte Cytoskeleton Disorders Diagnostic Core. Principal Investigator. CCTST PCS T1 Pilot. July 2013- June 2015.

    Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.

    TCD with Transfusions Changing to Hydroxyurea. Co-investigator. NIH/Baylor. Aug 2009-Jul 2014. #R01HL095647.

    A photo of Charles Quinn, MD.

    Charles T. Quinn, MD, MS
    Director, Hematology Clinical and Translational Research

    513-636-4266

    charles.quinn@cchmc.org

    Charles T. Quinn, MD, MS

    Director, Hematology Clinical and Translational Research

    Director, Hemoglobinopathy Laboratory

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-5845

    Email: charles.quinn@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke

    Research Interests

    Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)

    Biography

    Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

    Education and Training

    MD:  University of Texas Southwestern Medical Center, Dallas, TX, 1994.

    MS:  University of Texas Southwestern Medical Center, Dallas, TX, 2008.

    Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

    Fellowship:  Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

    Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

    Publications

    View PubMed Publications

    Grants

    A feasibility study of regadenoson for the treatment of acute chest syndrome. Co-investigator. National Institutes of Health. April 2012-March 2017. P50HL110790.

    Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.


    Psychologist

    A photo of Lori Crosby.

    Lori E. Crosby, PsyD
    Clinical Psychologist, Behavioral Medicine and Clinical Psychology

    513-636-4336

    lori.crosby@cchmc.org

    Lori E. Crosby, PsyD

    Clinical Psychologist, Behavioral Medicine and Clinical Psychology

    Co-Director, Innovations

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4336

    Fax: 513-636-7756

    Email: lori.crosby@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Adolescents; sickle cell disease; transition; chronic pain; migraines; cultural competence

    Research Interests

    Community-based research; self-management; quality improvement; sickle cell disease; health disparities

    Visit the Crosby Lab.

    Education and Training

    PsyD: Wright State University, Dayton, Ohio, 1995.

    Residency: Cincinnati Children's Hospital Medical Center.

    Fellowship: Clinical Psychology, INTERACT Behavioral Healthcare Services Inc, Columbus, OH, 1995-1996.

    Publications

    View PubMed Publications

    Grants

    Ohio Valley Sickle Cell Network. Co-Investigator. US Department of Health and Human Services. September 2010 - August 2014.